Liver Transplant News and Research

RSS

When a patient presents with end stage liver disease or liver failure he or she may be considered for a liver transplantation. The first step in this is often a rigorous assessment and being placed on a waiting list.

Innovative detection practices may prevent liver diseases

Research being presented at Digestive Disease Week- shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease.

9 May 2011

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Clinicians, researchers and scientists from around the world will gather for Digestive Disease Week- 2011, the largest and most prestigious gastroenterology meeting, from May 7-10, 2011, at McCormick Place, Chicago, IL.

7 May 2011

Five Loyola employees donate kidneys to complete strangers

Loyola University Medical Center is believed to be the first organization in the country, and perhaps the world, in which five employees have each donated kidneys to complete strangers with no strings attached.

28 Apr 2011

Panel speakers to discuss hepatitis C prevention, treatment at Mayes College event

Mayes College of Healthcare Business and Policy at University of the Sciences is hosting a panel discussion on hepatitis C prevention and treatment, on Thursday, April 28, 2011, from 5 to 7 p.m.

28 Apr 2011

ISCO completes first series of hepatocytes preclinical testing

International Stem Cell Corporation announces successful completion of the first series of preclinical testing of hepatocytes derived in the lab from human parthenogenetic stem cells.

27 Apr 2011

Transplanting cells from healthy adult livers may help treat genetic liver-lung disorder

Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation.

22 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Quest Diagnostics launches AccuType IL28B test for HCV

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection.

From Quest Diagnostics 18 Apr 2011

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.

15 Apr 2011

HALT-C trial reveals high mortality rates among patients with HCV

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis.

8 Apr 2011

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

A three-year follow-up study of patients in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial revealed that increased mortality among patients with advanced chronic hepatitis C who received long-term peginterferon therapy was attributed to non-liver related causes and occurred primarily in patients with bridging fibrosis. No pattern to this excess mortality was evident to researchers, but deaths were unrelated to the peginterferon treatment. Full findings are published in the April issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases (AASLD).

7 Apr 2011

Donation after cardiac death may broaden the scope of organ donor selection

Findings from two new studies presented today at the International Liver CongressTM confirm that there are options for clinicians to expand the pool of liver grafts for use in patients with liver disease.

1 Apr 2011

OPO staff working with ICU team can help recover more organs from brain dead donors

More than twice as many lungs and nearly 50 percent more kidneys could be recovered for transplant operations if intensive care physicians were to work with organ procurement organization (OPO) coordinators to monitor and manage donor bodies after brain death has occurred, according to an analysis by UPMC and University of Pittsburgh School of Medicine physicians that is now in the online version of the American Journal of Transplantation.

1 Apr 2011

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Study shows, for the first time, the successful reprogramming of diseased human hepatocytes into induced pluripotent stem cells (iPSC).

1 Apr 2011

Study confirms D-penicillamine and trientine effective against Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

1 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Positive results from Intercept OCA Phase II trial in patients with PBC

Intercept Pharmaceuticals, Inc., today announced positive results from a 59 patient, placebo controlled, double-blind Phase II clinical trial of obeticholic acid given as monotherapy to patients with primary biliary cirrhosis.

1 Apr 2011

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

MSD, known as Merck in the United States and Canada, announced today that final results from the two pivotal Phase III studies of VICTRELIS, its investigational oral hepatitis C protease inhibitor, will be published in the March 31st edition of The New England Journal of Medicine.

31 Mar 2011

Master regulators of cholesterol and fat play key role in liver fibrosis development

UCLA researchers have demonstrated that a key regulator of cholesterol and fat metabolism in the liver also plays an important role in the development of liver fibrosis - the build-up of collagen scar tissue that can develop into cirrhosis. Cirrhosis, in turn, is a major cause of premature death and is incurable without a liver transplant.

31 Mar 2011

Three-drug cocktail more effective against hepatitis C virus

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen, according to researchers at Henry Ford Hospital.

31 Mar 2011

Liver Transplant News and Research

Further Reading

Innovative detection practices may prevent liver diseases

AGA's cutting-edge research on GI disorders to be presented at DDW 2011

Five Loyola employees donate kidneys to complete strangers

Panel speakers to discuss hepatitis C prevention, treatment at Mayes College event

ISCO completes first series of hepatocytes preclinical testing

Transplanting cells from healthy adult livers may help treat genetic liver-lung disorder

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Quest Diagnostics launches AccuType IL28B test for HCV

Cytonet initiates clinical trial using liver cell infusion to treat urea cycle disorders in children

HALT-C trial reveals high mortality rates among patients with HCV

Increased mortality rates seen in chronic Hep C patients with pre-cirrhotic advanced fibrosis

Donation after cardiac death may broaden the scope of organ donor selection

OPO staff working with ICU team can help recover more organs from brain dead donors

Diseased human hepatocytes successfully reprogrammed into induced pluripotent stem cells

Study confirms D-penicillamine and trientine effective against Wilson disease

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Positive results from Intercept OCA Phase II trial in patients with PBC

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Master regulators of cholesterol and fat play key role in liver fibrosis development

Three-drug cocktail more effective against hepatitis C virus

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News